Cytokines &
Interleukin
ELISA Kits
GENLISA™ validated sandwich ELISA for quantitative cytokine measurement in serum, plasma, and cell culture supernatant across 16+ species. Plus PrecisionBind™ — the only Krishgen cytokine ELISA validated across serum, plasma, and CSF for CGT immune monitoring and ICANS. 1,000+ published citations.
Cytokine ELISA — Format, Validation & Selection
No single cytokine tells the full inflammatory story. Cytokine profiles — the relative abundance of pro-inflammatory, anti-inflammatory, and regulatory mediators measured simultaneously — define the inflammatory state. This requires a portfolio where all key targets are available from a single supplier with matched antibody pairs, consistent lot numbers, and proven cross-species coverage. Krishgen has manufactured cytokine ELISA since 2008 with 1,000+ citations across these kits.
All GENLISA™ cytokine ELISA use a sandwich immunoassay format — a capture monoclonal antibody pre-coated to the plate binds the target cytokine, followed by an HRP-conjugated detection antibody. Signal is directly proportional to cytokine concentration. Each kit is validated against six quality dimensions: sensitivity, specificity, intra-assay precision, inter-assay precision, accuracy (spike-recovery), and robustness/stability.
Pre-coated monoclonal antibody plates, HRP-conjugated detection antibody, and recombinant cytokine standard in one ready-to-use kit. Validated in serum, plasma, and cell culture supernatant. Intra-assay CV <15%. Recovery 80–120%. Available across 16+ species with matched antibody pairs — the same cytokine target available in Human, Mouse, Rat, Bovine, and Equine using species-optimised pairs. Genbulk™ format (5-plate / 15-plate) available for high-throughput workflows.
The same sandwich architecture with extended matrix validation covering serum, plasma, and cerebrospinal fluid (CSF) — the only Krishgen cytokine ELISA formally validated for CSF. NIBSC international standard calibration ensures inter-laboratory harmonization. Intra-assay CV <4%, inter-assay CV <5% across 50+ independent production lots. R² ≥0.995 linearity. Designed for Cell and Gene Therapy immune monitoring (CRS/ICANS), regulatory submissions, and multi-site clinical trials.
| Requirement | GENLISA™ Standard | PrecisionBind™ |
|---|---|---|
| Serum / Plasma | ✓ Validated | ✓ Validated |
| Cell culture supernatant | ✓ Validated | ✓ Validated |
| CSF (ICANS / neuroinflammation) | Not validated | ✓ Formally validated |
| NIBSC international calibration | Selected kits only | All kits |
| Intra-assay CV | <15% | <4% |
| Inter-assay CV | <20% | <5% |
| Production lots validated per analyte | Standard QC | 50+ independent lots |
| Best for | Research, biomarker studies, screening | CGT, clinical trials, multi-site studies |
Most Cited Cytokine ELISA Kits
Citation data sourced from BioZ.com — an independent publication tracking platform monitoring peer-reviewed journals worldwide. The kits below are Krishgen’s most-cited cytokine ELISA across all species, reflecting researcher confidence validated through published, reproducible data. Multi-species coverage of the same target (e.g. IL-6 across Rat, Mouse, Human, and Rabbit) reflects the breadth of Krishgen’s cross-species ELISA portfolio.
Citations Tracked
Citation data sourced from BioZ.com. Counts reflect independently verified peer-reviewed publications citing the named Krishgen ELISA kit. Data current as of Q1 2026. Full citation list available at krishgen.com/product-citations.
The Core Cytokine ELISA Panel
The six cytokines below define the core inflammatory readout in the majority of immunology studies. Each is available in Human, Mouse, Rat, Bovine, and Equine as a minimum — with many covering 10+ additional species. All use monoclonal capture and detection antibody pairs for specificity within the cytokine family.
The primary CRS biomarker and tocilizumab intervention target. IL-6 is produced by macrophages, T cells, and fibroblasts in response to infection and immune activation. Drives acute phase response, fever, and B cell differentiation. Elevated in sepsis, RA, COVID-19 cytokine storm, and post-CAR-T CRS — typically rising 12–24h post-infusion. PrecisionBind™ version available for CSF studies.
Primary inflammasome effector and anakinra / canakinumab target. IL-1β is processed from pro-IL-1β by Caspase-1 activated by the NLRP3 or other inflammasomes. Drives fever, leukocyte recruitment, and IL-6 production. Elevated in autoinflammatory diseases, gout, atherosclerosis, and NASH. PrecisionBind™ version achieves LOD 0.1 pg/mL — 30× more sensitive than most commercial kits.
Archetypal pro-inflammatory cytokine and primary target of the world’s best-selling biologic drug class (adalimumab, infliximab, etanercept). Produced primarily by macrophages and T cells; drives NF-κB activation, apoptosis, vascular permeability, and leukocyte recruitment. Elevated in RA, IBD, psoriasis, sepsis, and CRS. Among the most cited research ELISA in immunology globally.
Primary Th1 effector cytokine and key macrophage activation signal. Produced by activated T cells and NK cells; drives M1 macrophage polarization and anti-viral/anti-tumour immunity. A core CRS biomarker — grade 3–4 CRS in CAR-T therapy is characterised by IFN-γ elevation. Central to HLH diagnosis. NIBSC 95/554 calibrated PrecisionBind™ version available (LOD 3.6 pg/mL, CSF-validated).
Primary anti-inflammatory cytokine — the counter-regulatory signal that defines inflammation resolution. Produced by Tregs, macrophages, and B cells; suppresses pro-inflammatory cytokine production. Monitoring IL-10 alongside IL-6 and TNF-α provides a complete pro/anti-inflammatory readout. Elevated IL-10 in CRS can mask severity — it should always be included in CGT monitoring panels. PrecisionBind™ version: LOD 2.97 pg/mL, CSF-validated.
Master immunosuppressive and fibrogenic cytokine. TGF-β1 drives Treg differentiation and is the primary driver of fibrosis in NASH, IPF, and kidney disease. A key readout in Treg biology, transplant tolerance, and cancer immune evasion. TGF-β2 and TGF-β3 isoform kits also available. All three receptors (TGFBR1/2/3) available as matched receptor ELISA.
PrecisionBind™ Cytokine ELISA
Cell and gene therapy studies require cytokine quantification beyond what standard research ELISA can provide. PrecisionBind™ closes three critical gaps: CSF matrix validation for ICANS detection, NIBSC-calibrated standards for inter-laboratory harmonization, and ultra-high precision for clinical-grade data generation.
The primary tocilizumab intervention trigger; rises 12–24h post CAR-T infusion. PrecisionBind™ extends standard plasma/serum validation to include formal CSF matrix validation — essential for distinguishing systemic CRS from CNS-directed ICANS. NIBSC IL-6 calibrated. Intra-assay CV <4%. Contact technical team for catalog number.
Grade 3–4 CRS indicator. NIBSC 95/554 calibrated — 1 IU = 55.9 pg/mL equivalence confirmed. Traceability to international reference materials enables direct data comparison across studies and sites. CSF-validated for ICANS neurotoxicity grading. Intra-assay CV <3%.
Macrophage activation marker and anakinra intervention target. The highest-sensitivity Krishgen cytokine ELISA — LOD 0.1 pg/mL is approximately 30× more sensitive than most commercial IL-1β kits. Essential for detecting low-level IL-1β in clinical CSF samples. Recovery ±10% across serum, plasma, and CSF.
Myeloid amplifier and key CRS cytokine. NIBSC 88/646 calibrated for fully traceable quantification. GM-CSF blockade (mavrilimumab, lenzilumab) is being evaluated to reduce CRS severity. Part of the 7-analyte ASTCT-aligned CRS monitoring panel alongside IL-6, IFN-γ, IL-1β, IL-10, IL-8, and TNF-α.
Species Coverage — same target, species-specific validated kits
Th1 / Th2 / Th17 Cytokine Profiling
CD4+ T helper cell polarization defines the character of the adaptive immune response. Measuring the balance between Th1, Th2, Th17, and Treg cytokine outputs guides mechanistic understanding of autoimmunity, allergy, infection response, and vaccine immunogenicity.
Driven by IL-12 from dendritic cells; characterised by IFN-γ and IL-2 production. Th1 responses drive macrophage activation and cytotoxic T cell expansion against intracellular pathogens and tumours. Th1 dominance is associated with organ-specific autoimmune diseases (type 1 diabetes, MS, Crohn’s). IL-18 synergises with IL-12 to amplify IFN-γ production.
Driven by IL-4; characterised by IL-4, IL-5, IL-13 production. Th2 responses drive B cell class switching to IgE, eosinophil recruitment, and allergic inflammation. IL-4/13 are targets of dupilumab in atopic dermatitis and asthma. IL-25 (IL-17E) amplifies type 2 immunity by activating ILC2s. Th2 dominance is associated with allergy and atopic disease.
Driven by TGF-β + IL-6; characterised by IL-17A/F, IL-22, and IL-21 production. Th17 cells defend mucosal surfaces but their overactivation drives psoriasis, IBD, RA, and ankylosing spondylitis. IL-17A and IL-23 are major biologic targets (secukinumab, ixekizumab, guselkumab, risankizumab). Treg/Th17 ratio is a key mechanistic read-out in autoimmunity and transplant tolerance.
Interferon ELISA Kits
The interferons bridge innate and adaptive immunity. Type I interferons (IFN-α, IFN-β) are produced rapidly by virus-infected cells and pDCs to establish an antiviral state. Type II (IFN-γ) is produced by T cells and NK cells as an adaptive immune effector. Type III interferons (IFN-λ / IL-28/29) protect mucosal surfaces without the systemic inflammatory effects of type I IFNs.
IFN-α is produced by plasmacytoid dendritic cells (pDCs) as the dominant innate antiviral response. Elevated in SLE (IFN-α signature), viral infections, and type I interferonopathies — making it a key diagnostic biomarker. Individual subtype ELISA available: IFNA1, IFNA2, IFNA4, IFNA8, IFNA10, IFNA13, IFNA14. IFN-α receptor (IFNAR1) ELISA also available — key in SLE (anifrolumab mechanism).
IFN-λ1 (IL-29), IFN-λ2 (IL-28A), and IFN-λ3 (IL-28B) signal through IFNLR1/IL-10Rβ expressed predominantly on epithelial cells, protecting mucosal barriers in the gut and lung against viral infection without systemic inflammatory effects of type I IFNs. IL-28B genotype (rs12979860) is a key predictor of HCV treatment response — IL-28B ELISA supports translational studies.
Colony Stimulating Factors & Related Cytokines
Colony stimulating factors drive the production, survival, and activation of myeloid immune cells. GM-CSF is a key amplifier in cytokine storm. G-CSF expands neutrophils and is used clinically to treat chemotherapy-induced neutropenia. LIF and OSM belong to the IL-6 family and modulate inflammation, tissue repair, and stem cell biology.
G-CSF (CSF3) is the primary driver of granulopoiesis — neutrophil production in the bone marrow. Elevated G-CSF mobilises neutrophils during infection. Recombinant G-CSF (filgrastim, pegfilgrastim) is a major biopharmaceutical; G-CSF ELISA supports preclinical efficacy and PK studies of G-CSF biosimilars. Available in Human (KBH0121), Mouse (KLM0641), Rat (KLR0428), Porcine, and Rabbit.
GM-CSF (CSF2) drives macrophage and granulocyte production and activates myeloid cells in inflammation. A key amplifier in cytokine storm — GM-CSF blockade (mavrilimumab, lenzilumab) is being evaluated to reduce CRS severity. NIBSC 88/646 calibrated PrecisionBind™ version (1 IU = 166.8 pg/mL). Core component of ASTCT CRS monitoring panel alongside IL-6, IFN-γ, IL-1β, and others.
Leukemia Inhibitory Factor (LIF) and Oncostatin M (OSM) are IL-6 family cytokines that share the gp130 receptor. LIF is essential for embryo implantation and neural stem cell maintenance. OSM drives acute phase responses and is elevated in inflammatory arthritis and skin inflammation. Both modulate immune cell differentiation and tissue remodelling. Human, Mouse, Rat validated.
Cytokine & Interleukin Reference Table
Core Krishgen cytokine ELISA with catalog numbers. All kits validated: CV <15%, spike-recovery 80–120%. Full species coverage and extended interleukin range available at krishgen.com/cytokines. CoA and validation reports on request.
| Cat # | Target | Category | Series | Species | Key Application | Link |
|---|---|---|---|---|---|---|
| KB1068 | IL-6Interleukin-6 | Pro-inflammatory | GENLISA™ | Human | CRS biomarker · acute phase · tocilizumab target | View → |
| KB2068 | IL-6Mouse | Pro-inflammatory | GENLISA™ | Mouse | Preclinical inflammation · colitis · arthritis models | View → |
| KB3068 | IL-6Rat | Pro-inflammatory | GENLISA™ | Rat | Rat preclinical inflammation models | View → |
| KB1063 | IL-1βInterleukin-1 beta | NLRP3 / Inflammasome | GENLISA™ | Human | Inflammasome output · NLRP3 · anakinra / canakinumab target | View → |
| KB2063 | IL-1βMouse | NLRP3 / Inflammasome | GENLISA™ | Mouse | Murine NLRP3 / inflammasome studies | View → |
| KB1145 | TNF-αTumor Necrosis Factor alpha | Pro-inflammatory | GENLISA™ | Human | Master inflammatory cytokine · anti-TNF biologic target | View → |
| KB2145 | TNF-αMouse | Pro-inflammatory | GENLISA™ | Mouse | Mouse inflammatory & disease models | View → |
| KB1053 | IFN-γInterferon gamma | Th1 / Antiviral | GENLISA™NIBSC | Human | Th1 effector · CRS grade marker · HLH diagnosis | View → |
| KB2011 | IFN-γMouse | Th1 / Antiviral | GENLISA™ | Mouse | Mouse Th1 & anti-tumour immune response | View → |
| KB1072 | IL-10Interleukin-10 | Anti-inflammatory | GENLISA™ | Human | Immune resolution · Treg effector · CRS panel | View → |
| KB1075 | IL-12Interleukin-12 p70 | Th1 polariser | GENLISA™ | Human | Dendritic cell output · Th1 polarisation | View → |
| KB1066 | IL-4Interleukin-4 | Th2 | GENLISA™ | Human | Th2 driver · IgE class switch · dupilumab mechanism | View → |
| KB1067 | IL-5Interleukin-5 | Th2 / Eosinophil | GENLISA™ | Human | Eosinophil growth factor · asthma · mepolizumab target | View → |
| KB1076 | IL-13Interleukin-13 | Th2 | GENLISA™ | Human | Airway inflammation · dupilumab mechanism | View → |
| KB1079 | IL-17AInterleukin-17A | Th17 | GENLISA™ | Human | Th17 effector · psoriasis · secukinumab / ixekizumab target | View → |
| KB1086 | IL-22Interleukin-22 | Th17 / Epithelial | GENLISA™ | Human | Mucosal barrier integrity · IBD · psoriasis | View → |
| KBH2162 | IL-23Interleukin-23 p19 | Th17 driver | GENLISA™ | Human | Th17 maintenance · psoriasis / IBD · guselkumab / risankizumab | View → |
| KB1082 | IL-18Interleukin-18 | Inflammasome | GENLISA™ | Human | IFN-γ inducer · caspase-1 output · HLH | View → |
| KB1089 | IL-33Interleukin-33 · Alarmin | IL-1 Family / Alarmin | GENLISA™ | Human | ST2 axis · ILC2 activation · asthma · itepekimab target | View → |
| KB1088 | IL-31Interleukin-31 · Pruritus signal | Skin / Allergy | GENLISA™ | Human | Itch signal · atopic dermatitis · nemolizumab target | View → |
| KBH0134 | TGF-β1Transforming Growth Factor beta 1 | Regulatory / Fibrosis | GENLISA™ | Human | Treg induction · fibrosis driver · NASH / IPF biomarker | View → |
| KBH0121 | G-CSFGranulocyte Colony Stimulating Factor | Colony Stimulating Factor | GENLISA™ | Human | Neutrophil production · filgrastim / pegfilgrastim biosimilar PK | View → |
| KB1048 | GM-CSFGranulocyte-Macrophage CSF | Colony Stimulating Factor | GENLISA™NIBSC | Human | CRS myeloid amplifier · mavrilimumab target · NIBSC 88/646 | View → |
| KBH0076 | IFN-αInterferon alpha · Type I | Type I Interferon | GENLISA™ | Human | Antiviral innate response · SLE IFN-α signature | View → |
| KBH3000 | IL-1RAIL-1 Receptor Antagonist | IL-1 Family Regulator | GENLISA™ | Human | Endogenous IL-1 inhibitor · anakinra mechanism marker | View → |
| KBH1111 | LIFLeukemia Inhibitory Factor | IL-6 Family | GENLISA™ | Human | Embryo implantation · neural stem cell maintenance | View → |
| KBH1663 | OSMOncostatin M | IL-6 Family | GENLISA™ | Human | Joint inflammation · skin disease · gp130 family | View → |
| KBPB† | IL-6 PrecisionBind™CSF-validated · NIBSC-calibrated · LOD 3 pg/mL | CGT Immune Monitoring | PrecisionBind™ | Human | CRS detection · ICANS · clinical trials · regulatory-grade | View → |
| KBPB† | IFN-γ PrecisionBind™NIBSC 95/554 · LOD 3.6 pg/mL · CSF-validated | CGT Immune Monitoring | PrecisionBind™ | Human | CRS grading · HLH diagnosis · multi-site studies | View → |
| KBPB† | IL-1β PrecisionBind™LOD 0.1 pg/mL · Ultra-sensitive · CSF-validated | CGT Immune Monitoring | PrecisionBind™ | Human | Macrophage activation · anakinra target · lowest available LOD | View → |
| KBPB† | IL-10 PrecisionBind™LOD 2.97 pg/mL · CSF-validated | CGT Immune Monitoring | PrecisionBind™ | Human | Counter-regulatory CRS signal · immune resolution marker | View → |
| KBPB† | GM-CSF PrecisionBind™NIBSC 88/646 · 1 IU = 166.8 pg/mL | CGT Immune Monitoring | PrecisionBind™ | Human | Myeloid amplifier · mavrilimumab target · CRS panel | View → |
† PrecisionBind™ catalog numbers — please confirm exact codes with the Krishgen technical team at info@krishgen.com. Full cytokine catalogue across all 16+ species at krishgen.com/cytokines.
Frequently Asked Questions
GENLISA™ cytokine ELISA are available for Human, Mouse, Rat, Bovine, Equine, Porcine, Goat, Sheep, Chicken, Guinea Pig, Monkey (Rhesus), Canine, Rabbit, Cat, Hamster, and a General/Universal format for some analytes — 16+ species total. Each kit uses species-specific antibody pairs developed for that organism’s cytokine sequence. Cross-species use is not validated and not recommended.
Use PrecisionBind™ when you need: (1) CSF matrix validation for ICANS or neuroinflammation studies, (2) NIBSC-calibrated results for multi-site or regulatory-grade data, (3) ultra-low LOD (IL-1β: 0.1 pg/mL; IL-8: 0.2 pg/mL) for clinical samples, or (4) intra-assay CV below 4%. For standard research applications in serum/plasma/cell supernatant, GENLISA™ provides excellent performance at a lower price point.
No. A Human IL-6 ELISA (KB1068) will not accurately detect Mouse IL-6 — the antibodies are raised against human IL-6 epitopes that differ from mouse IL-6. You need Mouse IL-6 ELISA (KB2068) for mouse samples. Krishgen provides matched species-specific kits for all core cytokines, enabling true cross-species comparability with consistently architected assays.
The ASTCT consensus criteria recommend monitoring: IL-6 (primary tocilizumab trigger), IFN-γ (grade 3–4 indicator), IL-1β (macrophage activation; anakinra target), IL-10 (counter-regulatory), GM-CSF (myeloid amplifier), TNF-α (vascular permeability), and IL-8 (neutrophil recruitment). For ICANS, all should additionally be measured in CSF — PrecisionBind™ is the only Krishgen series with formal CSF validation.
All GENLISA™ cytokine kits are validated against six dimensions: sensitivity (LOD/LLOQ), specificity (cross-reactivity panel with related cytokines), intra-assay precision (CV within one run), inter-assay precision (CV across multiple runs/lots), accuracy (spike-recovery in validated matrices), and robustness/stability (accelerated at 37°C across 14 days). Full Certificate of Analysis and extended validation reports available on request per lot number.
Genbulk™ kits supply the three antibody components (capture, detection, standard/calibrator) in bulk volumes for 5 or 15 plates. The user must supply and optimise their own blocking buffer, substrate, and coating solutions. Genbulk™ is appropriate for established high-throughput workflows with validated methods. It is not recommended for occasional users or method development — use GENLISA™ ready-to-use kits in those cases.
Can’t Find Your Cytokine or Species?
Our technical team can source species-specific kits not listed here, configure bundled cytokine panels, advise on PrecisionBind™ vs GENLISA™ selection, or develop custom assays for novel targets.
